Neural Cell Isolation via FACS Marker Sorting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating human embryonic stem cells into neural cell populations result in heterogeneous cultures with varying stages of maturation, hindering therapeutic and experimental applications due to the presence of cells at different developmental stages, which can lead to undesirable effects like tumor formation.
Innovation Solution
The isolation and characterization of specific neural cell populations using CD15, CD24, and CD29 markers, combined with gentle fluorescence-activated cell sorting (FACS) techniques, to produce homogeneous populations of early neurons, neural crest cells, and neural precursor cells that can be further enriched for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current differentiation protocols are used to generate neural cell populations from human embryonic stem cells, then cell production is achieved, but cellular heterogeneity with respect to developmental stage and lineage specification occurs
Solution Approach 1:
The patent segments the heterogeneous neural cell population into distinct subpopulations based on cell surface marker expression patterns (CD133, CD24, CD29, CD44, CD49f). Flow cytometry sorting separates cells into early neuronal progenitors, intermediate neural progenitors, and mature neurons based on their specific marker profiles, thereby resolving the heterogeneity problem while maintaining productivity
Solution Approach 2:
The patent utilizes changes in cell surface marker expression parameters (CD133, CD24, CD29, CD44, CD49f) as cells differentiate through developmental stages. By monitoring and sorting based on these parameter changes, the method achieves synchronization of cell populations at defined stages of maturation, transforming the heterogeneous mixture into homogeneous, stage-specific populations
2Adaptability or versatility
If cells at different stages of maturation are present in differentiated hESC cultures, then broad cellular heterogeneity is achieved, but experimental, clinical, and therapeutic utilization is impeded
Solution Approach 1:
The patent performs preliminary sorting of neural cell populations at defined stages of differentiation before therapeutic application. By pre-separating early neuronal progenitors (CD133+, CD24+, CD29-, CD44-, CD49f-) from intermediate and mature cells, the method ensures that only synchronized, stage-appropriate populations are used for therapy, eliminating the operational difficulties caused by cellular heterogeneity
Solution Approach 2:
The patent replaces manual or mechanical cell separation methods with flow cytometry-based sorting using fluorescently labeled antibodies against cell surface markers. This substitution enables precise, rapid, and scalable separation of neural cell subpopulations based on their marker expression profiles, greatly improving ease of operation and therapeutic utilization
3Reliability
If cell transplantation therapies are used to treat neurodegenerative disease, then therapeutic effect is achieved, but tumor formation risk remains due to presence of proliferative cell populations
Solution Approach 1:
The patent extracts and removes proliferative neural stem and progenitor cell populations (characterized by CD133+, CD24+, CD29+, CD44+, CD49f+ expression) from the differentiated cell culture before transplantation. By taking out these potentially tumorigenic cells and retaining only post-mitotic neurons and mature differentiated cells, the method maintains therapeutic effect while eliminating tumor formation risk
Solution Approach 2:
The patent exploits parameter changes in cell surface marker expression that occur during neural differentiation. As cells mature, they downregulate stem cell markers (CD133, CD24, CD29, CD44, CD49f) and upregulate neuronal markers. By sorting based on these parameter changes, the method ensures transplantation of only mature, non-proliferative cells, thereby preventing tumor formation while preserving therapeutic benefits
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach yields homogeneous populations of neural cells with defined characteristics, reducing tumor formation potential and enhancing their therapeutic efficacy for neurodegenerative disease treatments by ensuring consistent cellular morphology and marker expression, thereby improving the safety and effectiveness of cell transplantation therapies.
Implementation Method 1
gentle fluorescence-activated cell sorting (FACS) techniques
Data Source
AI summary
The inventions disclosed herein are based on the identification of novel cell populations derived from human embryonic stem cells and other pluripotent cells. The inventive cell populations may be used for cell therapies for the treatment of various neurological diseases and as substrates in pharmacological assays.